Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...

The International Society for Pharmaceutical Engineering (ISPE) has announced its keynote speakers at the 2025 ISPE Biotechnology Conference, taking place Monday, 2 June, through Tuesday, 3 June, in ...

Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated ...

Plus: JetBlue CEO eyes more growth in Boston; AG Andrea Campbell offers fiery words about Trump; Charles River chamber offers ...

"We are a significant player. But yes, we are not very well-known yet. And that's part of my job — to get to know the right ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Initiated Phase 1/2 combination study of micvotabart pelidotin and Merck’s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors. We aim to select a ...

Merck — the multinational that made billions of dollars from ... an endocrinologist and professor at Harvard University in ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated to produce bulk substance for its megablockbuster HPV vaccine Gardasil.